Patents by Inventor Matthew Vanneman

Matthew Vanneman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NKG2D-IG fusion protein for cancer immunotherapy
    Patent number: 11851472
    Abstract: Methods and compositions for cancer immunotherapy are provided. The methods involve the use of a chimeric molecule (e.g., fusion protein) comprising a dimeric NKG2D portion and an Fc portion, which binds one or more NKG2D ligands. In some embodiments, the molecule further comprises a drug moiety (e.g., an IL15/Ra moiety). The methods disclosed herein are useful for the treatment of cancer that is associated with abnormal expression of one or more NKG2D ligands.
    Type: Grant
    Filed: November 12, 2020
    Date of Patent: December 26, 2023
    Inventors: Glenn Dranoff, Ryan Sullivan, Matthew Vanneman
  • NKG2D-FC FOR IMMUNOTHERAPY
    Publication number: 20220002382
    Abstract: Methods for cancer immunotherapy are provided. The methods involve the use of a chimeric molecule (e.g., fusion protein) comprising an NKG2D portion and an Fc portion, which binds one or more NKG2D ligands. The methods disclosed herein are useful for the treatment of cancer that is associated with abnormal expression of one or more NKG2D ligands.
    Type: Application
    Filed: April 2, 2021
    Publication date: January 6, 2022
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Glenn Dranoff, Matthew Vanneman, Gordon Freeman
  • NKG2D-IG FUSION PROTEIN FOR CANCER IMMUNOTHERAPY
    Publication number: 20210130434
    Abstract: Methods and compositions for cancer immunotherapy are provided. The methods involve the use of a chimeric molecule (e.g., fusion protein) comprising a dimeric NKG2D portion and an Fc portion, which binds one or more NKG2D ligands. In some embodiments, the molecule further comprises a drug moiety (e.g., an IL15/Ra moiety). The methods disclosed herein are useful for the treatment of cancer that is associated with abnormal expression of one or more NKG2D ligands.
    Type: Application
    Filed: November 12, 2020
    Publication date: May 6, 2021
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Glenn Dranoff, Ryan Sullivan, Matthew Vanneman
  • NKG2D-fc for immunotherapy
    Patent number: 10865233
    Abstract: Methods for cancer immunotherapy are provided. The methods involve the use of a chimeric molecule (e.g., fusion protein) comprising an NKG2D portion and an Fc portion, which binds one or more NKG2D ligands. The methods disclosed herein are useful for the treatment of cancer that is associated with abnormal expression of one or more NKG2D ligands.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: December 15, 2020
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Glenn Dranoff, Matthew Vanneman, Gordon Freeman
  • NKG2D-IG fusion protein for cancer immunotherapy
    Patent number: 10865232
    Abstract: Methods and compositions for cancer immunotherapy are provided. The methods involve the use of a chimeric molecule (e.g., fusion protein) comprising a dimeric NKG2D portion and an Fc portion, which binds one or more NKG2D ligands. In some embodiments, the molecule further comprises a drug moiety (e.g., an IL15/Ra moiety). The methods disclosed herein are useful for the treatment of cancer that is associated with abnormal expression of one or more NKG2D ligands.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: December 15, 2020
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Glenn Dranoff, Ryan Sullivan, Matthew Vanneman
  • AN NKG2D-IG FUSION PROTEIN FOR CANCER IMMUNOTHERAPY
    Publication number: 20180355013
    Abstract: Methods and compositions for cancer immunotherapy are provided. The methods involve the use of a chimeric molecule (e.g., fusion protein) comprising a dimeric NKG2D portion and an Fc portion, which binds one or more NKG2D ligands. In some embodiments, the molecule further comprises a drug moiety (e.g., an IL15/Ra moiety). The methods disclosed herein are useful for the treatment of cancer that is associated with abnormal expression of one or more NKG2D ligands.
    Type: Application
    Filed: November 11, 2016
    Publication date: December 13, 2018
    Inventors: Glenn Dranoff, Ryan Sullivan, Matthew Vanneman
  • NKG2D-FC FOR IMMUNOTHERAPY
    Publication number: 20110311535
    Abstract: Methods for cancer immunotherapy are provided. The methods involve the use of a chimeric molecule (e.g., fusion protein) comprising an NKG2D portion and an Fc portion, which binds one or more NKG2D ligands. The methods disclosed herein are useful for the treatment of cancer that is associated with abnormal expression of one or more NKG2D ligands.
    Type: Application
    Filed: December 18, 2009
    Publication date: December 22, 2011
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Glenn Dranoff, Matthew Vanneman, Gordon Freeman